Ocular Therapeutix
OCUL
64 hedge funds and large institutions have $201M invested in Ocular Therapeutix in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 16 closing their positions.
386% more call options, than puts
Call options by funds: $788K | Put options by funds: $162K
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
2% more capital invested
Capital invested by funds: $197M → $201M (+$3.54M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less funds holding
Funds holding: 71 → 64 (-7)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$4.91M |
| 2 |
B
Bailard
Foster City,
California
|
+$1.66M |
| 3 |
CI
Cowen Inc
New York
|
+$990K |
| 4 |
D.E. Shaw & Co
New York
|
+$680K |
| 5 |
CCI
Columbus Circle Investors
|
+$649K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.02M |
| 2 |
Millennium Management
New York
|
-$2.6M |
| 3 |
O
OrbiMed
New York
|
-$1.45M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.42M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$898K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$92.1K | -12,155 | Closed |
|
77
Citadel Advisors
Miami,
Florida
| – | -$72.3K | -9,542 | Closed |
|
78
Simplex Trading
Chicago,
Illinois
| – | -$36.4K | -4,810 | Closed |
|
79
BNP Paribas Financial Markets
Paris,
France
| – | -$25.9K | -2,766 | Closed |
|
|
TRCT
80
Tower Research Capital (TRC)
New York
| – | -$10K | -1,026 | Closed |
|
OCUL Hedge Fund Activity: Q1 2016 in Review
64 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2016, worth a combined $201M — up 1.8% from $197M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OCUL and 9 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 21 added.
The largest buyer was Jennison Associates, adding an estimated $4.91M. The largest seller was Fidelity Investments, cutting an estimated $4.02M.
- 64 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2016, down from 71 in Q4 2015.
- Funds reported $201M of Ocular Therapeutix stock for Q1 2016, up 1.8% quarter-over-quarter.
- 9 funds opened new Ocular Therapeutix positions in Q1 2016 and 16 closed out, a net change of -7 holders.
- The largest Ocular Therapeutix buyer in Q1 2016 was Jennison Associates, an estimated $4.91M added.
- The largest Ocular Therapeutix seller in Q1 2016 was Fidelity Investments, an estimated $4.02M sold.
Based on aggregated 13F filings for Q1 2016.